Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,959.00
Bid: 1,952.00
Ask: 1,954.00
Change: 20.00 (1.03%)
Spread: 2.00 (0.102%)
Open: 1,940.00
High: 1,971.00
Low: 1,940.00
Prev. Close: 1,939.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BROKER RATINGS: Downgrades for Centrica and Rathbones

Fri, 06th May 2022 09:47

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

----------

FTSE 100

----------

UBS raises Shell price target to 2,550 (2,450) pence - 'buy'

----------

Goldman Sachs raises Shell price target to 39 (37) EUR - 'buy'

----------

Jefferies raises Mondi price target to 1,775 (1,700) pence - 'buy'

----------

Morgan Stanley cuts Hikma Pharmaceuticals target to 2,100 (2,300) pence - 'equal weight'

----------

HSBC raises Flutter Entertainment price target to 14,900 (14,700) pence - 'buy'

----------

Deutsche Bank cuts Hargreaves price target to 1160 (1250) pence - 'hold'

----------

Berenberg cuts Barratt Developments price target to 790 (810) pence - 'buy'

----------

Goldman Sachs cuts Next price target to 8,200 (8,500) pence - 'buy'

----------

RBC raises HSBC price target to 590 (550) pence - 'outperform'

----------

FTSE 250

----------

Liberum raises Trainline price target to 435 (400) pence - 'buy'

----------

Morgan Stanley raises Trainline price target to 310 (270) p - 'equal-weight'

----------

Barclays raises Trainline price target to 280 (200) pence - 'underweight'

----------

Morgan Stanley cuts Travis Perkins target to 1,870 (2,000) pence - 'overweight'

----------

HSBC cuts Centrica to 'reduce' (hold)

----------

Citigroup cuts Direct Line price target to 286 (317) pence - 'buy'

----------

JPMorgan raises Beazley price target to 670 (650) pence - 'overweight'

----------

Barclays raises Virgin Money price target to 245 (225) pence - 'equal weight'

----------

RBC raises Greencoat UK Wind price target to 200 (170) pence - 'outperform'

----------

UBS raises Man Group price target to 305 (285) pence - 'buy'

----------

UBS cuts Jupiter Fund price target to 180 (210) pence - 'neutral'

----------

Jefferies cuts Rathbones to 'hold' (buy) - price target 2,100 (1,900) pence

----------

Jefferies raises Qinetiq price target to 405 (350) pence - 'buy'

----------

Jefferies raises Chemring Group price target to 350 (300) pence - 'hold'

----------

JPMorgan raises Hiscox price target to 895 (870) pence - 'underweight'

----------

Morgan Stanley raises Hiscox price target to 1,194 (1,159) pence - 'overweight'

----------

SMALL CAP

----------

Barclays cuts Reach price target to 135 (185) pence - 'equal weight'

----------

RBC raises Greencoat Renewables price target to 1.50 (1.30) pence - outperform

----------

Goldman Sachs starts Petrofac with 'buy' - price target 170 pence

----------

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
3 Jan 2023 09:25

Hikma launches version of Xyrem medicine in US for treating narcolepsy

(Alliance News) - Hikma Pharmaceuticals PLC on Tuesday said it launched an authorised generic version of the Xyrem sodium oxybate prescription medicine in the US for treating narcolepsy.

Read more
3 Jan 2023 09:24

LONDON BROKER RATINGS: Citigroup cuts Wizz Air; Redburn likes CRH

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning, Monday and late Friday:

Read more
3 Jan 2023 09:03

LONDON MARKET OPEN: Stocks jump in first session of 2023

(Alliance News) - Stock prices in London made a strong start to the new year on Tuesday, despite weak Chinese data and the UK suffering a fresh wave of rail strikes.

Read more
3 Jan 2023 07:58

LONDON BRIEFING: Stocks called higher; China factory sector shrinks

(Alliance News) - Stocks in London are expected to start a new year on the front foot on Tuesday, after a mixed session in Asia amid weak Chinese economic data.

Read more
3 Jan 2023 07:46

Hikma launches generic narcolepsy solution in US

(Sharecast News) - Hikma Pharmaceuticals has launched an authorised generic version of Jazz Pharmaceuticals' 'Xyrem 1', or sodium oxybate oral solution, it announced on Tuesday.

Read more
8 Dec 2022 09:48

LONDON BROKER RATINGS: JPMorgan cuts Travis Perkins; BofA likes IAG

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
6 Dec 2022 10:48

RBC Capital Markets starts Hikma at 'outperform'

(Sharecast News) - RBC Capital Markets initiated coverage of Hikma Pharmaceuticals on Tuesday at 'outperform' with a 1,750p price target.

Read more
6 Dec 2022 10:26

LONDON BROKER RATINGS: JPMorgan cuts Lloyds but raises Barclays

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
15 Nov 2022 12:10

Credit Suisse initiates coverage of Hikma at 'outperform'

(Sharecast News) - Credit Suisse has initiated coverage of Hikma Pharmaceuticals with an 'outperform' rating.

Read more
15 Nov 2022 09:58

LONDON BROKER RATINGS: Jefferies cuts Aston Martin to 'underperform'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
14 Nov 2022 09:25

LONDON BROKER RATINGS: Credit Suisse cuts Ferrexpo to 'neutral'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
8 Nov 2022 09:39

LONDON BROKER RATINGS: Peel cuts Persimmon; Liberum raises Hammerson

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
3 Nov 2022 11:17

Hikma Pharmaceuticals reiterates 2022 guidance as costs widen

(Alliance News) - Hikma Pharmaceuticals PLC on Thursday reiterated annual guidance for all three of its businesses, continuing to expect them to underperform against 2021 due to rising costs.

Read more
3 Nov 2022 11:08

With tighter purse strings, is parity less probable for the pound?

STOXX 600 down 1.1%

*

Read more
3 Nov 2022 09:28

Banks, insurance dodge carnage as real estate stocks sink

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at .

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.